Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + FOLFIRI in RAS-mutated mCRC
NCT05522738Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in metastatic colorectal cancer (mCRC), sponsored by Chinese PLA General Hospital. Started Aug 2022; status: recruiting.
02
Drugs
fruquintinib
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT05522738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05522738.